Immuneering to Participate in the Cowen 44th Annual Health Care Conference
05 March 2024 - 12:00AM
Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology
company seeking to develop and commercialize universal-RAS/RAF
medicines for broad populations of cancer patients,
today announced that management will participate in the Cowen
44th Annual Health Care Conference, which is taking place at the
Marriott Copley Place in Boston from March 4-6, 2024, to discuss
the company’s pipeline, platform, and business strategy.
Participating will be Ben Zeskind, Chief Executive Officer, Brett
Hall, Chief Scientific Officer, Harold “E.B.” Brakewood, Chief
Business Officer, and Mallory Morales, Chief Accounting Officer,
Treasurer.
Format: Panel Discussion and 1x1 Investor
MeetingsPanel Discussion: Titled ‘Targeted Oncology’ on March 5
from 12:50 to 1:50 PM ET
The presentations will be webcast live and
archived in the Investor Relations section of Immuneering’s website
at Events & Presentations | Immuneering Corporation.
About Immuneering
Corporation
Immuneering is a clinical-stage oncology company
seeking to develop and commercialize universal-RAS/RAF medicines
for broad populations of cancer patients with an initial aim to
develop a universal-RAS therapy. The Company aims to achieve
universal activity through deep cyclic inhibition of the MAPK
pathway, impacting cancer cells while sparing healthy cells.
Immuneering’s lead product candidate, IMM-1-104, is an oral,
once-daily deep cyclic inhibitor currently in a Phase 1/2a study in
patients with advanced solid tumors harboring RAS mutations.
IMM-6-415 is an oral, twice-daily deep cyclic inhibitor and will be
evaluated in a Phase 1/2a study in patients with advanced solid
tumors harboring RAS or RAF mutations. The company’s development
pipeline also includes several early-stage programs. For more
information, please visit www.immuneering.com.
Media Contact:Gina
Nugent Nugent
Communications 617-460-3579 gina@nugentcommunications.com
Investor
Contacts: Laurence Watts Gilmartin
Group 619-916-7620 laurence@gilmartinir.com
or
Kiki Patel, PharmD Gilmartin
Group 332-895-3225kiki@gilmartinir.com
Immuneering (NASDAQ:IMRX)
Historical Stock Chart
From Apr 2024 to May 2024
Immuneering (NASDAQ:IMRX)
Historical Stock Chart
From May 2023 to May 2024